Search

Your search keyword '"Rosner, Bernard"' showing total 38 results
Start Over Author "Rosner, Bernard" Journal new england journal of medicine
38 results on '"Rosner, Bernard"'

2. Long-Term Colorectal-Cancer Incidence and Mortality after Lower Endoscopy

Author

Nishihara, Reiko, primary, Wu, Kana, additional, Lochhead, Paul, additional, Morikawa, Teppei, additional, Liao, Xiaoyun, additional, Qian, Zhi Rong, additional, Inamura, Kentaro, additional, Kim, Sun A., additional, Kuchiba, Aya, additional, Yamauchi, Mai, additional, Imamura, Yu, additional, Willett, Walter C., additional, Rosner, Bernard A., additional, Fuchs, Charles S., additional, Giovannucci, Edward, additional, Ogino, Shuji, additional, and Chan, Andrew T., additional

Published
2013
Full Text
View/download PDF

3. Performance of Common Genetic Variants in Breast-Cancer Risk Models

Author

Wacholder, Sholom, primary, Hartge, Patricia, additional, Prentice, Ross, additional, Garcia-Closas, Montserrat, additional, Feigelson, Heather Spencer, additional, Diver, W. Ryan, additional, Thun, Michael J., additional, Cox, David G., additional, Hankinson, Susan E., additional, Kraft, Peter, additional, Rosner, Bernard, additional, Berg, Christine D., additional, Brinton, Louise A., additional, Lissowska, Jolanta, additional, Sherman, Mark E., additional, Chlebowski, Rowan, additional, Kooperberg, Charles, additional, Jackson, Rebecca D., additional, Buckman, Dennis W., additional, Hui, Peter, additional, Pfeiffer, Ruth, additional, Jacobs, Kevin B., additional, Thomas, Gilles D., additional, Hoover, Robert N., additional, Gail, Mitchell H., additional, Chanock, Stephen J., additional, and Hunter, David J., additional

Published
2010
Full Text
View/download PDF

7. Postmenopausal Hormone Therapy and Mortality

Author

Grodstein, Francine, primary, Stampfer, Meir J., additional, Colditz, Graham A., additional, Willett, Walter C., additional, Manson, JoAnn E., additional, Joffe, Marshall, additional, Rosner, Bernard, additional, Fuchs, Charles, additional, Hankinson, Susan E., additional, Hunter, David J., additional, Hennekens, Charles H., additional, and Speizer, Frank E., additional

Published
1997
Full Text
View/download PDF

9. Lack of Effect of Long-Term Supplementation with Beta Carotene on the Incidence of Malignant Neoplasms and Cardiovascular Disease

Author

Hennekens, Charles H., primary, Buring, Julie E., additional, Manson, JoAnn E., additional, Stampfer, Meir, additional, Rosner, Bernard, additional, Cook, Nancy R., additional, Belanger, Charlene, additional, LaMotte, Frances, additional, Gaziano, J. Michael, additional, Ridker, Paul M., additional, Willett, Walter, additional, and Peto, Richard, additional

Published
1996
Full Text
View/download PDF

11. Alcohol Consumption and Mortality among Women

Author

Fuchs, Charles S., primary, Stampfer, Meir J., additional, Colditz, Graham A., additional, Giovannucci, Edward L., additional, Manson, JoAnn E., additional, Kawachi, Ichiro, additional, Hunter, David J., additional, Hankinson, Susan E., additional, Hennekens, Charles H., additional, Rosner, Bernard, additional, Speizer, Frank E., additional, and Willett, Walter C., additional

Published
1995
Full Text
View/download PDF

33. Dietary Fat and the Risk of Breast Cancer

Author

Willett, Walter C., primary, Stampfer, Meir J., additional, Colditz, Graham A., additional, Rosner, Bernard A., additional, Hennekens, Charles H., additional, and Speizer, Frank E., additional

Published
1987
Full Text
View/download PDF

36. Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality.

Author

Yang Hu, Geng Zong, Gang Liu, Wang, Molin, Rosner, Bernard, An Pan, Willett, Walter C., Manson, JoAnn E., Hu, Frank B., Qi Sun, Hu, Yang, Zong, Geng, Liu, Gang, Pan, An, and Sun, Qi

Subjects
*CARDIOVASCULAR disease prevention, *CAUSES of death, *LONGITUDINAL method, *TYPE 2 diabetes, *RESEARCH funding, *SMOKING cessation, *WEIGHT gain, *PROPORTIONAL hazards models, CARDIOVASCULAR disease related mortality
Abstract

Background: Whether weight gain after smoking cessation attenuates the health benefits of quitting is unclear.Methods: In three cohort studies involving men and women in the United States, we identified those who had reported quitting smoking and we prospectively assessed changes in smoking status and body weight. We estimated risks of type 2 diabetes, death from cardiovascular disease, and death from any cause among those who had reported quitting smoking, according to weight changes after smoking cessation.Results: The risk of type 2 diabetes was higher among recent quitters (2 to 6 years since smoking cessation) than among current smokers (hazard ratio, 1.22; 95% confidence interval [CI], 1.12 to 1.32). The risk peaked 5 to 7 years after quitting and then gradually decreased. The temporary increase in the risk of type 2 diabetes was directly proportional to weight gain, and the risk was not increased among quitters without weight gain (P<0.001 for interaction). In contrast, quitters did not have a temporary increase in mortality, regardless of weight change after quitting. As compared with current smokers, the hazard ratios for death from cardiovascular disease were 0.69 (95% CI, 0.54 to 0.88) among recent quitters without weight gain, 0.47 (95% CI, 0.35 to 0.63) among those with weight gain of 0.1 to 5.0 kg, 0.25 (95% CI, 0.15 to 0.42) among those with weight gain of 5.1 to 10.0 kg, 0.33 (95% CI, 0.18 to 0.60) among those with weight gain of more than 10.0 kg, and 0.50 (95% CI, 0.46 to 0.55) among longer-term quitters (>6 years since smoking cessation). Similar associations were observed for death from any cause.Conclusions: Smoking cessation that was accompanied by substantial weight gain was associated with an increased short-term risk of type 2 diabetes but did not mitigate the benefits of quitting smoking on reducing cardiovascular and all-cause mortality. (Funded by the National Institutes of Health.). [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

37. Nut Consumption and Mortality.

Author

Elin, Ronald J., Kopel, Eran, Kivity, Shaye, Sidi, Yechezkel, Ying Bao, Rosner, Bernard A., and Fuchs, Charles S.

Subjects
*FOOD habits research, *NUTS, *MORTALITY
Abstract

Letters to the editor are presented in response to the study by Bao and colleagues on the inverse association between nut consumption and mortality in the November 21, 2013 issue.

Published
2014
Full Text
View/download PDF

38. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.

Author

Singer DE, Hughes RA, Gress DR, Sheehan MA, Oertel LB, Maraventano SW, Blewett DR, Rosner B, and Kistler JP

Subjects
Aged, Aged, 80 and over, Aspirin therapeutic use, Atrial Fibrillation mortality, Female, Hemorrhage chemically induced, Humans, Male, Middle Aged, Prothrombin Time, Risk, Warfarin adverse effects, Warfarin therapeutic use, Atrial Fibrillation complications, Cerebrovascular Disorders prevention & control, Warfarin administration & dosage
Abstract

Background: Nonrheumatic atrial fibrillation increases the risk of stroke, presumably from atrial thromboemboli. There is uncertainty about the efficacy and risks of long-term warfarin therapy to prevent stroke., Methods: We conducted an unblinded, randomized, controlled trial of long-term, low-dose warfarin therapy (target prothrombin-time ratio, 1.2 to 1.5) in patients with nonrheumatic atrial fibrillation. The control group was not given warfarin but could choose to take aspirin., Results: A total of 420 patients entered the trial (212 in the warfarin group and 208 in the control group) and were followed for an average of 2.2 years. Prothrombin times in the warfarin group were in the target range 83 percent of the time. Only 10 percent of the patients assigned to receive warfarin discontinued the drug permanently. There were 2 strokes in the warfarin group (incidence, 0.41 percent per year) as compared with 13 strokes in the control group (incidence, 2.98 percent per year), for a reduction of 86 percent in the risk of stroke (warfarin:control incidence ratio = 0.14; 95 percent confidence interval, 0.04 to 0.49; P = 0.0022). There were 37 deaths altogether. The death rate was markedly lower in the warfarin group than in the control group: 2.25 percent as compared with 5.97 percent per year, for an incidence ratio of 0.38 (95 percent confidence interval, 0.17 to 0.82; P = 0.005). There was one fatal hemorrhage in each group. The frequency of bleeding events that led to hospitalization or transfusion was essentially the same in both groups. The warfarin group had a higher rate of minor hemorrhage than the control group (38 vs. 21 patients)., Conclusions: Long-term low-dose warfarin therapy is highly effective in preventing stroke in patients with non-rheumatic atrial fibrillation, and can be quite safe with careful monitoring.

Published
1990
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results